Physician profile
Anne Ellen Wacker
NPI 1225743354
$4,007.52
in general payments reported to CMS, 2019-2025
31 companies · $2,395 in 2025
The $2,395 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $957 · 2024: $655 · 2025: $2,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,728 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,728.28 |
| Education | $279.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $392.78 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $333.18 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $275.99 | 2025 | |
| Janssen Biotech, INC. | $259.37 | 2025 | Tremfya |
| Incyte Corporation | $257.13 | 2025 | Opzelura |
| Genzyme Corporation | $247.31 | 2025 | |
| Lilly USA, LLC | $232.04 | 2023-2025 | Mounjaro, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $231.07 | 2025 | Nemluvio |
| Amgen INC. | $212.48 | 2023-2025 | Otezla, Otezla, Repatha |
| Novo Nordisk INC | $174.65 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $143.34 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $139.35 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $130.86 | 2025 | Dupixent |
| Dexcom, INC. | $129.00 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $121.13 | 2025 | Sotyktu |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $118.45 | 2023 | Epclusa |
| Sanofi-Aventis U.S. LLC | $95.64 | 2024-2025 | |
| Indivior INC. | $79.72 | 2023-2024 | Sublocade |
| Merck Sharp & Dohme LLC | $72.04 | 2023 | Verquvo |
| Ucb, INC. | $70.11 | 2025 | Bimzelx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.25 | 2024-2025 | Caplyta |
| Braeburn INC. | $45.11 | 2023-2024 | Brixadi |
| Alexion Pharmaceuticals, INC. | $38.78 | 2023 | |
| Janssen Scientific Affairs, LLC | $37.22 | 2025 | Tremfya |
| Corcept Therapeutics | $28.87 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $25.25 | 2025 | |
| Globus Medical, INC. | $20.46 | 2025 | Senza |
| Inari Medical, INC. | $17.68 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $15.50 | 2025 | |
| Mayne Pharma Commercial LLC | $9.54 | 2025 | |
| Organon LLC | $6.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Wacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.